NEW YORK (GenomeWeb) – Proteomics-based diagnostics firm Ascendant Dx today said that it closed on a $2 million funding round, which will support clinical trials for and commercialization of its tears-based breast cancer detection test.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: global genetic diversity map, and more.
The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.
In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."
Stat News reports that there's muted opposition to the Kuwaiti DNA database law.